ClinicalTrials.gg
RecruitingNCT06595953Updated Nov 9, 2026

Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety

A Phase 2 interventional study of Gaze-Contingent Music Reward Therapy in Psychiatric Disorders and Anxiety Disorders, sponsored by National Institute of Mental Health (NIMH). Recruiting at 1 site in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Primary conditionAnxiety DisordersRegistry: Mental DisordersReclassifiedWhy we changed it
Registry
Mental Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Anxiety Disorders
Why
  1. The study's listed conditions name Anxiety Disorders, a narrower term within Mental Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Institute of Mental Health (NIMH) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
8 Years to 17 Years
Sex
All
01

Study summary

Background:

Anxiety disorders are becoming more common among children and teenagers. Anxiety can lead to long-term physical and mental problems, such as depression. Treatments for anxiety disorders include medications as well as cognitive behavioral therapy (CBT); CBT is a form of talking therapy. Both approaches work in only about 50 percent of cases. A new approach, called gaze-contingent music reward therapy (GCMRT), may help.

Objective:

To find out whether GCMRT combined with CBT is more effective than CBT alone.

Eligibility:

Children aged 8 to 17 years with separation anxiety disorder; generalized anxiety disorder; or social anxiety disorder. They must be enrolled in protocol 01-M-0192.

Design:

Participants will come to the clinic once a week for 4 weeks for CBT. Sometimes the participant will meet with the doctor alone; sometimes their parent may be present. They will do some computer-based tasks: They may be asked to push a button when a target appears; they may look at pictures of faces while the computer tracks their eye movements. Participants will take questionnaires each week. They will answer questions about their anxiety symptoms, feelings, and behavior.

For the next 8 weeks, participants will participate in both CBT and 1 of 2 types of GCMRT.

GCMRT is a computer-based task. Participants will look at pictures with many faces in them; while they do this, pleasant music will play and stop playing over a 12-minute period.

Participants will have a final visit in week 13. They will take questionnaires. They will do final research tasks. Each visit lasts about 2 hours.

Read the detailed description

Study Description:

This study compares the efficacy of Gaze-Contingent Music Reward Therapy (GCMRT) and a control form of GCMRT, both added to concurrent therapy. Efficacy will be examined for the severity of clinician-rated anxiety in medication-free children and adolescents with an anxiety disorder. For concurrent therapy, all patients will receive Cognitive Behavioral Therapy (CBT). With this design, efficacy is based on comparison of groups receiving CBT augmented with either active or control forms of GCMRT. A total of 150 patients will be enrolled in the study and will begin CBT therapy for three weeks. By the end of week three, participants will be randomly assigned in a one-to-one ratio to the two forms of GCMRT, which they will receive along with CBT for 9 weeks. From among the 150 patients who enroll in the study, 120 are expected to be randomized to one of the two forms of GCMRT.

Objectives:

Primary Objective: To test the efficacy of Gaze-Contingent Music Reward Therapy (GCMRT) for the augmentation of Cognitive Behavioral Therapy (CBT) treatment for pediatric anxiety disorders.

Secondary Objective: To test for efficacy on secondary outcome measures as well as to test for moderation and mediation of efficacy by measures of attention bias.

Endpoints:

Primary Endpoint: The severity of clinician-rated anxiety, blinded to the GCMRT condition, on the Pediatric Anxiety Rating Scale (PARS).

Secondary Endpoints: Overall treatment response on the clinician-rated Clinician Global Impression scale and rated symptoms of anxiety on the Screen for Child Anxiety Related Disorders (SCARED) scale, as completed by parents and patients.

02

Conditions studied

  • Psychiatric Disorders
  • Anxiety Disorders

Browse trials for

Keywords

  • Cognitive-behavioral therapy
  • Attention
  • Anxiety
  • Children
  • Adolescents
03

In context

Anxiety Disorders Reclassified

7,201 studies on the registry are indexed under Anxiety Disorders; 1,682 are open to participants now.

This study's planned enrollment of 150 is above the median of 80 across 6,057 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

National Institute of Mental Health (NIMH) is the lead sponsor of 367 studies on the registry; 45 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 24 (96%) have results posted.

Compared within Anxiety Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mental Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Ability of subject and parent to understand the study and the willingness to assent/consent into the study.
  2. Males and females; Age 8-17
  3. Clinician confirmed diagnosis of ongoing separation anxiety disorder, generalized anxiety disorder, or social anxiety disorder. A clinician will review a KSADS-PL (November 2016) (Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged Children) interview, which will have occurred on Protocol 01-M-0192, to confirm diagnosis
  4. Willingness to adhere to 12 weekly in-person sessions of CBT
  5. Enrolled in Protocol 01-M-0192
  6. Subjects must speak, read and write English to be able to participate
  7. All subjects will have IQ>70 as assessed by a WASI or assessment by trained clinical staff which will have occurred under Protocol 01-M-0192

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Current use of any psychotropic medication
  2. Ongoing participation in another treatment or intervention study
  3. Ongoing mental health treatment outside of NIH
  4. Any mental health diagnosis aside from an anxiety disorder as determined by the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS)
  5. Any serious medical conditions
  6. Restrictions that preclude in-person attendance of therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Active-GCMRT

    In the active form of the therapy, music stops when subjects view negative valence faces.

    Behavioral: Gaze-Contingent Music Reward Therapy

  • Sham comparator
    Sham-GCMRT

    In the control condition, music plays continuously.

    Behavioral: Gaze-Contingent Music Reward Therapy

Interventions

  • BehavioralGaze-Contingent Music Reward Therapy

    All subjects will receive CBT and will be randomized to either active or control forms of GCMRT. This involves the monitoring of a patient s eye-movements during the free-viewing of computer-displayed matrices of faces expressing various emotions in tandem with the playing of pleasant music. In the active form of the therapy, music stops when subjects view negative valence faces, whereas in the control condition, music plays continuously. Subjects undergo 12 weeks of CBT, where GCMRT is delivered in the last eight weeks of therapy.

06

What researchers measure

Primary outcomes

  1. Pediatric Anxiety Rating Scale (PARS)

    Completed by the clinician.

    Time frame: Week 1-13.

Secondary outcomes

  1. Clinical Global Impression Scale (CGI)

    Completed by the clinician.

    Time frame: Week 1-13.

  2. Screen for Child Anxiety Related Disorders (SCARED)

    Completed by parents and patients.

    Time frame: Week 1, 4, and 13.

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • NIH Clinical Center Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

7 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Oct 2029, 57 months after the start.

Of 81 non-industry phase 2 interventional studies under Anxiety Disorders, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's planned 57 months is above that.

Counting every sponsor, half of 96 studies reached it within 35 months; a quarter within 18 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2024
First posted
Sep 19, 2024
StartActual
Dec 4, 2024
Primary completionEst.
Oct 1, 2029
CompletionEst.
Oct 1, 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: description and verification date
7 updates, last Nov 9, 2026
Show all 7 updates
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: description
  2. Nov 5, 2026
    Minor edits only
    + 1 other change: description
  3. Oct 13, 2026
    Minor edits only
    + 1 other change: description
  4. Oct 8, 2026
    Minor edits only
    + 1 other change: description
  5. Oct 5, 2026
    Minor edits only
    + 1 other change: verification date
  6. Oct 2, 2026
    Minor edits only
    + 1 other change: description
  7. Sep 28, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06595953
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Dec 4, 2024
Primary completion
Oct 1, 2029 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Daniel S Pine, M.D.
Contact
daniel.pine@nih.gov
(301) 594-1318
Daniel S Pine, M.D.
principal investigator · National Institute of Mental Health (NIMH)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion